Brief: Jiangsu Recbio Technology Says Completed First Batch Of Subject Enrollment For Phase Iii Clinical Trial Of Recov Vaccine
08/11/2022 09:39
Nov 8 (Reuters) - Jiangsu Recbio Technology Co Ltd
2179.HK :
* COMPLETED FIRST BATCH OF SUBJECT ENROLLMENT FOR PHASE III
CLINICAL TRIAL OF RECOV VACCINE
Source text for Eikon: ID:nHKS2rSVQ1
Further company coverage: 2179.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Jiangsu Recbio Technology
See all newsBrief: Jiangsu Recbio Technology To Re-Plan Timetable For HPV Vaccine Marketing Application
Brief: Jiangsu Recbio Technology Says New Drug Application For REC610 Shingles Vaccine Accepted By NMPA
Brief: Jiangsu Recbio Technology Says Liu Yong Resigned As Chair
Brief: Jiangsu Recbio Technology Says Li Bu Resigned As Executive Director
Brief: Jiangsu Recbio Technology Says Acceptance By CSRC Of Application Materials For Issuance Of Shares